https://ipharmag.com/article/scholar-rock-isembyld-apitegromab-sma-fda-approval iPharmag en 2026-09-12T14:23:59+00:00 FDA Approves First Muscle-Targeted Therapy for Spinal Muscular Atrophy https://ipharmag.com/article/nutromics-fda-breakthrough-antibiotic-monitoring-patch iPharmag en 2026-09-12T14:23:59+00:00 A Skin Patch That Tracks Antibiotic Levels in Real Time Wins FDA Breakthrough Status https://ipharmag.com/article/gilead-lenacapavir-nice-snub-hiv-prevention iPharmag en 2026-09-12T14:23:59+00:00 A Twice-a-Year Shot Could Transform HIV Prevention — but England’s NHS Won’t Fund It Yet https://ipharmag.com/article/bat-dna-longevity-immune-cancer-resistance iPharmag en 2026-09-12T14:23:59+00:00 Why Do Bats Live So Long Without Getting Cancer? Their DNA Offers Clues https://ipharmag.com/article/astrazeneca-camizestrant-serena4-breast-cancer-miss iPharmag en 2026-09-12T14:23:59+00:00 AstraZeneca’s Breast Cancer Pill Stumbles in First-Line Trial — a Week After an FDA Nod https://ipharmag.com/article/wtc-9-11-cancer-cases-25-years iPharmag en 2026-09-11T13:28:40+00:00 Twenty-Five Years After 9/11, Cancer Cases Among Survivors Keep Rising https://ipharmag.com/article/ucla-cord-blood-alloeso-t-cells-cancer iPharmag en 2026-09-11T13:28:40+00:00 Scientists Turn Donated Cord Blood Into an ‘Off-the-Shelf’ Cancer Cell Therapy https://ipharmag.com/article/time-restricted-eating-type-1-diabetes iPharmag en 2026-09-11T13:28:40+00:00 An 8-Hour Eating Window Improved Blood Sugar in Type 1 Diabetes — Safely, Small Study Finds https://ipharmag.com/article/fda-bayer-sevabertinib-hyrnuo-her2-lung-cancer-first-line iPharmag en 2026-09-11T13:28:40+00:00 FDA Clears Bayer’s Hyrnuo as a First-Line Option for HER2-Mutated Lung Cancer https://ipharmag.com/article/encoded-therapeutics-275m-dravet-gene-therapy iPharmag en 2026-09-11T13:28:40+00:00 Encoded Raises $275M to Push a One-Time Gene Therapy for a Severe Childhood Epilepsy